Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors

N/AEnrolling By InvitationNCT06285071

Novo Nordisk A/S23 enrolled

Overview

The purpose of the study is to investigate the safety and effectiveness of Alhemo® in all participants under real-world clinical practice in Japan. Participants will get Alhemo® as prescribed by the study doctor. The study will last for about 2 years.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Haemophilia A Haemophilia B

Interventions

ConcizumabDRUG

Participants will be treated with commercially available Alhemo (Concizumab) according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Concizumab has been made by the participant/ legally acceptable representative (LAR) and the treating physician before and independently from the decision to include the participant in this study.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) * The decision to initiate treatment with commercially available Alhemo® has been made by the patient/LAR and the treating physician before and independently from the decision to include the patient in this study * Male or female patients, regardless of age * Diagnosis with HAwI/HBwI Exclusion Criteria: \- Previous participation in this study. Participation is defined as having given informed consent in this study

Locations (7)

Novo Nordisk Investigational Site

Toshima City, Tokyo, Japan

Mutsu general hospital

Aomori, Japan

Kyushu university hospital_Pediatrics

Fukuoka, Japan

Sapporo Tokushukai Hospital_Pediatrics

Hokkaido, Japan